CRISPR Therapeutics Appoints Chief Business Officer
This article was originally published in Scrip
CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into cures for serious human diseases, has appointed Dr. Samarth Kulkarni chief business officer and Dr. Michael Bruce senior vice-president of program portfolio and alliance management.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.